Unclaimed brand
APIM Therapeutics. Disabling Cancer's Ability to Escape Treatment
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#83A5CA
Polo Blue
131, 165, 202
211, 40, 65
35, 18, 0, 21
#D7909D
Can Can
215, 144, 157
349, 47, 70
0, 33, 27, 16
#D76F0A
Christine
215, 111, 10
30, 91, 44
0, 48, 95, 16
APIM Therapeutics is a clinical-stage oncology company developing first-in-class therapeutics that target proliferating cell nuclear antigen (PCNA). Its approach focuses on disrupting PCNA-dependent cellular stress responses, which can help cancer cells resist treatment. The company aims to develop medicines for significant unmet medical needs, both as standalone treatments and in combination with existing cancer therapies.
APIM’s lead drug candidate, ATX-101, is a peptide therapeutic designed to target these stress responses. It has been evaluated in Phase Ib and Phase II clinical studies for ovarian cancer and soft tissue sarcoma. The company is also advancing a broader pipeline of peptide therapeutics directed at PCNA-dependent stress responses in cancer cells. Its work is intended to address treatment resistance and improve the potential effectiveness of cancer therapy.
Alongside research and development, APIM Therapeutics provides information for investors and pursues business development opportunities related to its pipeline. The company shares updates through its news, events, and publications channels, including information about patents protecting ATX-101 for sarcoma in major markets.
Company type
Privately Held
Year founded
2010
Company size
2-10 employees
